{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T22:56:49Z","timestamp":1773183409382,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Protein folding is a process of self-assembly defined by the sequence of the amino acids of the protein involved. Additionally, proteins tend to unfold, misfold and aggregate due to both intrinsic and extrinsic causes. Human islet amyloid polypeptide (hIAPP) aggregation is an early step in diabetes mellitus. However, the aggregation of rat IAPP (rIAPP) remains an open question. Adult female Sprague-Dawley rats weighing 150\u2013250\u2009g were divided into two groups. The experimental group (streptozotocin [STZ]) (n\u2009=\u200921) received an intraperitoneal injection of a single dose of 40\u2009mg\/kg STZ. We used the mouse anti-IAPP antibody and the anti-amyloid oligomer antibody to study the temporal course of rIAPP oligomerization during STZ-induced diabetes using a wide array of methods, strategies and ideas derived from biochemistry, cell biology, and proteomic medicine. Here, we demonstrated the tendency of rIAPP to aggregate and trigger cooperative processes of self-association or hetero-assembly that lead to the formation of amyloid oligomers (trimers and hexamers). Our results are the first to demonstrate the role of rIAPP amyloid oligomers in the development of STZ-induced diabetes in rats. The IAPP amyloid oligomers are biomarkers of the onset and progression of diabetes and could play a role as therapeutic targets.<\/jats:p>","DOI":"10.1038\/s41598-017-11776-y","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T10:51:34Z","timestamp":1505127094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel insight into streptozotocin-induced diabetic rats from the protein misfolding perspective"],"prefix":"10.1038","volume":"7","author":[{"given":"Edgar","family":"Leyva-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reyna","family":"Lara-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liborio","family":"Mor\u00e1n-Zanabria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Revilla-Monsalve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Felipe","family":"Jim\u00e9nez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norma","family":"Oviedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiharu","family":"Murata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eulalia","family":"Garrido-Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly F.","family":"Altamirano-Bustamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myriam M.","family":"Altamirano-Bustamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"11776_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.sbi.2009.01.006","volume":"19","author":"V Daggett","year":"2009","unstructured":"Daggett, V. & Fersht, A. R. Protein folding and binding: moving into unchartered territory. Curr. Opin. Struct. Biol. \n                           19, 1\u20132 (2009).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"11776_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","volume":"75","author":"F Chiti","year":"2006","unstructured":"Chiti, F. & Dobson, C. M. Protein Misfolding, Functional Amyloid, and Human Disease. Annu. Rev. Biochem. \n                           75, 333\u2013366 (2006).","journal-title":"Annu. Rev. Biochem."},{"key":"11776_CR3","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(97)02073-4","volume":"350","author":"RW Carrell","year":"1997","unstructured":"Carrell, R. W. & Lomas, D. A. Conformational disease. Lancet \n                           350, 134\u2013138 (1997).","journal-title":"Lancet"},{"key":"11776_CR4","doi-asserted-by":"publisher","first-page":"31374","DOI":"10.1074\/jbc.M400348200","volume":"279","author":"M Bucciantini","year":"2004","unstructured":"Bucciantini, M. et al. Prefibrillar amyloid protein aggregates share common features of cytotoxicity. J. Biol. Chem. \n                           279, 31374\u201331382 (2004).","journal-title":"J. Biol. Chem."},{"key":"11776_CR5","doi-asserted-by":"publisher","unstructured":"Bemporad, F. & Ramazzotti, M. From the Evolution of Protein Sequences Able to Resist Self-Assembly to the Prediction of Aggregation Propensity. Early Stage Protein Misfolding and Amyloid Aggregation, doi:https:\/\/doi.org\/10.1016\/bs.ircmb.2016.08.008 (Elsevier Inc., 2016).","DOI":"10.1016\/bs.ircmb.2016.08.008"},{"key":"11776_CR6","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.cell.2012.02.022","volume":"148","author":"D Eisenberg","year":"2012","unstructured":"Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell \n                           148, 1188\u20131203 (2012).","journal-title":"Cell"},{"key":"11776_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nature20416","volume":"539","author":"R Riek","year":"2016","unstructured":"Riek, R. & Eisenberg, D. S. The activities of amyloids from a structural perspective. Nature \n                           539, 227\u2013235 (2016).","journal-title":"Nature"},{"key":"11776_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.1079469","volume":"300","author":"R Kayed","year":"2003","unstructured":"Kayed, R. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis. Science (80-.). \n                           300, 486\u2013489 (2003).","journal-title":"Science (80-.)."},{"key":"11776_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","volume":"6","author":"U Sengupta","year":"2016","unstructured":"Sengupta, U., Nilson, A. N. & Kayed, R. The Role of Amyloid-?? Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine \n                           6, 42\u201349 (2016).","journal-title":"EBioMedicine"},{"key":"11776_CR10","unstructured":"American Diabetes Association. National Diabetes Statistics Report, 2014 Estimates of Diabetes and Its Burden in the Epidemiologic estimation methods. Natl. Diabetes Stat. Rep. 2009\u20132012 (2014)."},{"key":"11776_CR11","doi-asserted-by":"crossref","unstructured":"Brookmeyer, R., Johnson, E., Ziegler-Graham, K. & Arrighi, H. M. Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers.Dement. 3, 186\u2013191 (2007).","DOI":"10.1016\/j.jalz.2007.04.381"},{"key":"11776_CR12","unstructured":"INSP. Encuesta Nacional de Salud y Nutrici\u00f3n. Instituto Nacional de Salud P\u00fablica 1\u2013190 (2012)."},{"key":"11776_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0140-6736(87)90825-7","volume":"2","author":"A Clark","year":"1987","unstructured":"Clark, A. et al. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet (London, England) \n                           2, 231\u20134 (1987).","journal-title":"Lancet (London, England)"},{"key":"11776_CR14","doi-asserted-by":"crossref","unstructured":"Westermark, P., Andersson, A. & Westermark, G. T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 91, 795\u2013826","DOI":"10.1152\/physrev.00042.2009"},{"key":"11776_CR15","doi-asserted-by":"crossref","unstructured":"Akter, R. et al. Review Article Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology. J. Diabetes Res. 2016 (2016).","DOI":"10.1155\/2016\/2798269"},{"key":"11776_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.biocel.2005.12.009","volume":"38","author":"JW Hoppener","year":"2006","unstructured":"Hoppener, J. W. & Lips, C. J. Role of islet amyloid in type 2 diabetes mellitus. Int.J.Biochem.Cell Biol. \n                           38, 726\u2013736 (2006).","journal-title":"Int.J.Biochem.Cell Biol."},{"key":"11776_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.biochi.2010.12.012","volume":"93","author":"E Ahmad","year":"2011","unstructured":"Ahmad, E. et al. A mechanistic approach for islet amyloid polypeptide aggregation to develop anti-amyloidogenic agents for type-2 diabetes. Biochimie \n                           93, 793\u2013805 (2011).","journal-title":"Biochimie"},{"key":"11776_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0303-7207(95)03646-O","volume":"114","author":"H Mulder","year":"1995","unstructured":"Mulder, H., Ahr\u00e9n, B. & Sundler, F. Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol. Cell. Endocrinol. \n                           114, 101\u2013109 (1995).","journal-title":"Mol. Cell. Endocrinol."},{"key":"11776_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1126\/science.1104345","volume":"307","author":"CJ Rhodes","year":"2005","unstructured":"Rhodes, C. J. Type 2 Diabetes-a Matter of {beta}-Cell Life and Death? Science (80-.). \n                           307, 380\u2013384 (2005).","journal-title":"Science (80-.)."},{"key":"11776_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/368756a0","volume":"368","author":"A Lorenzo","year":"1994","unstructured":"Lorenzo, A., Razzaboni, B., Weir, G. C. & Yankner, B. A. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus. Nature \n                           368, 756\u2013760 (1994).","journal-title":"Nature"},{"key":"11776_CR21","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/416507a","volume":"416","author":"M Bucciantini","year":"2002","unstructured":"Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature \n                           416, 507\u2013511 (2002).","journal-title":"Nature"},{"key":"11776_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-5-57","volume":"5","author":"R Kayed","year":"2010","unstructured":"Kayed, R. et al. Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Ab oligomers. Mol. Neurodegener. \n                           5, 57 (2010).","journal-title":"Mol. Neurodegener."},{"key":"11776_CR23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0076-6879(06)13017-7","volume":"413","author":"R Kayed","year":"2006","unstructured":"Kayed, R. & Glabe, C. G. Conformation-Dependent Anti-Amyloid Oligomer Antibodies. Methods Enzymol. \n                           413, 326\u2013344 (2006).","journal-title":"Methods Enzymol."},{"key":"11776_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nature03680","volume":"435","author":"R Nelson","year":"2005","unstructured":"Nelson, R. et al. Structure of the cross-beta spine of amyloid-like fibrils. Nature \n                           435, 773\u2013778 (2005).","journal-title":"Nature"},{"key":"11776_CR25","first-page":"1","volume":"2013","author":"L Jiang","year":"2013","unstructured":"Jiang, L. et al. Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. Elife \n                           2013, 1\u201327 (2013).","journal-title":"Elife"},{"key":"11776_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/nchem.1433","volume":"4","author":"P-N Cheng","year":"2012","unstructured":"Cheng, P.-N., Liu, C., Zhao, M., Eisenberg, D. & Nowick, J. S. Amyloid \u03b2-sheet mimics that antagonize protein aggregation and reduce amyloid toxicity. Nat. Chem. \n                           4, 927\u201333 (2012).","journal-title":"Nat. Chem."},{"key":"11776_CR27","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s00125-010-1671-6","volume":"53","author":"S Zraika","year":"2010","unstructured":"Zraika, S. et al. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia \n                           53, 1046\u201356 (2010).","journal-title":"Diabetologia"},{"key":"11776_CR28","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1073\/pnas.96.7.3590","volume":"96","author":"F Chiti","year":"1999","unstructured":"Chiti, F. et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl. Acad. Sci. USA \n                           96, 3590\u20133594 (1999).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11776_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00125-003-1304-4","volume":"48","author":"A Clark","year":"2004","unstructured":"Clark, A. et al. Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia \n                           48, 157\u2013169 (2004).","journal-title":"Diabetologia"},{"key":"11776_CR30","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/BF00400803","volume":"36","author":"JWM H\u00f6ppener","year":"1993","unstructured":"H\u00f6ppener, J. W. M. et al. Chronic overproduction of islet amyloid polypeptide\/amylin in transgenic mice: lysosomal localization of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia \n                           36, 1258\u20131265 (1993).","journal-title":"Diabetologia"},{"key":"11776_CR31","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1021\/bi301525e","volume":"52","author":"L G.","year":"2013","unstructured":"G., L., J., Z. & X., Y. Comparative molecular dynamics study of human islet amyloid polypeptide (IAPP) and Rat IAPP oligomers. Biochemistry \n                           52, 1089\u20131100 (2013).","journal-title":"Biochemistry"},{"key":"11776_CR32","doi-asserted-by":"publisher","first-page":"10373","DOI":"10.1039\/C4CP05658B","volume":"17","author":"M Zhang","year":"2015","unstructured":"Zhang, M. et al. Interfacial interaction and lateral association of cross-seeding assemblies between hIAPP and rIAPP oligomers. Phys. Chem. Chem. Phys. \n                           17, 10373\u201382 (2015).","journal-title":"Phys. Chem. Chem. Phys."},{"key":"11776_CR33","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.transproceed.2012.05.079","volume":"45","author":"J Udayasankar","year":"2013","unstructured":"Udayasankar, J. et al. Rosiglitazone treatment does not decrease amyloid deposition in transplanted islets from transgenic mice expressing human islet amyloid polypeptide. Transplant. Proc. \n                           45, 574\u2013579 (2013).","journal-title":"Transplant. Proc."},{"key":"11776_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3322\/caac.21219","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward, E., DeSantis, C., Robbins, A., Kohler, B. & Jemal, A. Childhood and adolescent cancer statistics. CA. Cancer J. Clin. \n                           64, 83\u2013103 (2014).","journal-title":"CA. Cancer J. Clin."},{"key":"11776_CR35","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.1021\/jp5022246","volume":"118","author":"M Zhang","year":"2014","unstructured":"Zhang, M. et al. Structural and energetic insight into the cross-seeding amyloid assemblies of human IAPP and Rat IAPP. J. Phys. Chem. B \n                           118, 7026\u20137036 (2014).","journal-title":"J. Phys. Chem. B"},{"key":"11776_CR36","first-page":"1873","volume":"10","author":"HR Jeong","year":"2015","unstructured":"Jeong, H. R. & An, S. S. A. Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus. Clin. Interv. Aging \n                           10, 1873\u20131879 (2015).","journal-title":"Clin. Interv. Aging"},{"key":"11776_CR37","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1210\/jc.2004-0405","volume":"89","author":"RL Hull","year":"2004","unstructured":"Hull, R. L., Westermark, G. T., Westermark, P. & Kahn, S. E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J. Clin. Endocrinol. Metab. \n                           89, 3629\u20133643 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"11776_CR38","doi-asserted-by":"crossref","unstructured":"Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem.Sci. 24, 329\u2013332.","DOI":"10.1016\/S0968-0004(99)01445-0"},{"key":"11776_CR39","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/pro.145","volume":"18","author":"JJW Wiltzius","year":"2009","unstructured":"Wiltzius, J. J. W., Sievers, S. A., Sawaya, M. R. & Eisenberg, D. Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process. Protein Sci. \n                           18, 1521\u20131530 (2009).","journal-title":"Protein Sci."},{"key":"11776_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/srep04267","volume":"4","author":"Y Bram","year":"2014","unstructured":"Bram, Y. et al. Apoptosis induced by islet amyloid polypeptide soluble oligomers is neutralized by diabetes-associated specific antibodies. Sci. Rep. \n                           4, 4267 (2014).","journal-title":"Sci. Rep."},{"key":"11776_CR41","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJM200011233432106","volume":"343","author":"FH Epstein","year":"2000","unstructured":"Epstein, F. H., H\u00f6ppener, J. W. M., Ahr\u00e9n, B. & Lips, C. J. M. Islet Amyloid and Type 2 Diabetes Mellitus. N. Engl. J. Med. \n                           343, 411\u2013419 (2000).","journal-title":"N. Engl. J. Med."},{"key":"11776_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/pdb.prot091322","volume":"2017","author":"MK Morphew","year":"2017","unstructured":"Morphew, M. K., Giddings, T. H. & McIntosh, J. R. Immunolocalization of Proteins in Fission Yeast by Electron Microscopy. Cold Spring Harb. Protoc. \n                           2017, pdb.prot091322 (2017).","journal-title":"Cold Spring Harb. Protoc."},{"key":"11776_CR43","volume":"44","author":"R A.","year":"2015","unstructured":"A., R., D., B., A. K., D. & R., P. Aggregation of islet amyloid polypeptide (IAPP): At what stage does IAPP become sticky and toxic? European Biophysics Journal \n                           44, S208 (2015).","journal-title":"European Biophysics Journal"},{"key":"11776_CR44","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1073\/pnas.0507471103","volume":"103","author":"L-M Yan","year":"2006","unstructured":"Yan, L.-M. et al. Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis. Proc. Natl. Acad. Sci. USA \n                           103, 2046\u20132051 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11776_CR45","doi-asserted-by":"publisher","first-page":"46363","DOI":"10.1074\/jbc.C400260200","volume":"279","author":"R Kayed","year":"2004","unstructured":"Kayed, R. et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. \n                           279, 46363\u201346366 (2004).","journal-title":"J. Biol. Chem."},{"key":"11776_CR46","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1042\/BCJ20160026","volume":"473","author":"S Singh","year":"2016","unstructured":"Singh, S., Trikha, S., Sarkar, A. & Jeremic, A. M. Proteasome regulates turnover of toxic human amylin in pancreatic cells. Biochem. J. \n                           473, 2655\u20132670 (2016).","journal-title":"Biochem. J."},{"key":"11776_CR47","doi-asserted-by":"publisher","first-page":"28S","DOI":"10.1042\/bst021028s","volume":"21","author":"JW Hoppener","year":"1993","unstructured":"Hoppener, J. W. et al. IAPP\/amylin transgenic mice as an in vivo model system for type-2 diabetes mellitus? Biochem. Soc. Trans. \n                           21, 28S\u201328S (1993).","journal-title":"Biochem. Soc. Trans."},{"key":"11776_CR48","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2337\/diabetes.53.6.1509","volume":"53","author":"B A. E.","year":"2004","unstructured":"A. E., B. et al. Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): A new model for type 2 diabetes. Diabetes \n                           53, 1509\u20131516 (2004).","journal-title":"Diabetes"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11776-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11776-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:48:47Z","timestamp":1671792527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11776-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11776"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11776-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]},"assertion":[{"value":"23 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11552"}}